AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 122 min read$BMY

Bristol Myers (BMY) Addresses Adamilparant Trial Fatality as Sha

Bristol Myers Squibb (BMY) reported a patient fatality in the Phase 3 trial of adamilparant, a drug for idiopathic pulmonary fibrosis, but stated it was unlikely related to the medication. The company's shares fell 4% to $56.86. BMY offers a 4.27% dividend yield with a payout ratio of 41% and a GF Value of $56.76, indicating fair valuation. The company has a GF Score of 72, reflecting solid profitability and financial health.

Original reporting
gurufocus.com
Published Oct 12, 2026, 5:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 6:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BMY
Bearish
high confidence
Mentioned
$BMY
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$BMYBearishMed
01

Why it matters

The announcement triggered a 4% drop in BMY shares, highlighting market sensitivity to trial safety news.

02

Market read

First‑report safety news for a late‑stage trial; potential short‑term sell‑off in a large‑cap pharma stock.

03

What to watch

Higher than intended dosage could be a procedural error rather than a drug flaw.

Relevance 7/10Novelty 8/10Timing: intraday today

Background

Bristol Myers Squibb disclosed a patient death during its adamilparant Phase 3 trial, stating the event is unlikely linked to the drug.

Company-level read

Ticker impact

$BMYBearishHigh confidence
Context

Patient fatality in Phase 3 trial of adamilparant; company says unlikely drug‑related; shares fell 4% intraday.

Expected impact

likely pressure as market prices in safety concerns

Evidence & confidence

New fatality report in a late‑stage trial can trigger sell‑offs despite company disclaimer.

Market effects

Sector

Biotech and pharma stocks may face heightened scrutiny on trial safety.

Regional

US equity markets could see modest pullback in healthcare sector.

Global

Limited to investors with exposure to large‑cap pharma.

Counterpoint

What could challenge this read

The fatality may be an isolated dosing issue and not indicative of overall drug safety.

Key entities

  • company
    Bristol Myers Squibb

    US‑listed biopharma firm (NYSE:BMY) conducting Phase 3 trial of adamilparant.

Read at source← All news

StoryBristol Myers Squibb reports mixed Phase 3 results for admilparant in idiopathic pulmonary fibrosis

Also covered by

4 outlets

Related articles

OCT 12
$BMYMed

Bristol Myers Squibb (BMY) Reports Positive Phase 3 Trial Result

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for admilparant in treating idiopathic pulmonary fibrosis, showing significant lung function improvement at 60 mg. The company offers a 4.3% dividend yield, a 41% payout ratio, and a GF Score of 72, indicating strong fundamentals. BMY's stock is near a 5-year low P/E of 12.57x, suggesting potential value. Insider activity shows net selling, while guru ownership is mixed.

gurufocus.com4 min
OCT 12
$BMYMed

BMY's RYZ101 Meets Phase 3 Goal, Improving PFS In Advanced GEP-NETs

Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for RYZ101, an investigational radiopharmaceutical therapy. The study met its primary endpoint, showing a significant improvement in progression-free survival for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company plans to discuss next steps with the FDA. BMY shares are currently trading at $57.25, down 3.21%.

rttnews.com4 min
OCT 12
$BMYMed

Bristol Myers dips on ‘confounding’ lung drug results

Bristol Myers Squibb reported that its experimental lung disease drug admilparant showed mixed results in a Phase 3 trial, with only the 60 mg dose significantly slowing breathing decline in idiopathic pulmonary fibrosis patients. The 120 mg dose did not meet statistical significance, raising questions. The company stated the drug had a well-tolerated safety profile. Analysts and investors had concerns due to prior trial revisions and liver safety issues.

finance.yahoo.com6 min
OCT 12
$BMYMed

Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for

Bristol Myers Squibb (BMY) shares rose after positive Phase 3 results for RYZ101 and admilparant. RYZ101 showed improved progression-free survival in neuroendocrine tumors, while admilparant met primary endpoints in lung function decline. Both drugs face regulatory and market uncertainties. BMY aims to offset declining revenue with these innovations, but financial impact depends on approvals and adoption.

gurufocus.com5 min